

## Phase I Clinical Trial of Cell Based Therapy for Duchenne Muscular Dystrophy

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- diagnosed with Duchenne muscular dystrophy (DMD) and non-ambulatory - age 18 or older - off investigational treatments for at least 30 days

---

**Exclusion Criteria:**

- presence of HLA antibodies directed toward HLA antigens on MyoPAXon - active treatment with another investigational therapy - known allergy to MyoPAXon components

### Conditions & Interventions

**Interventions:**

Drug: MyoPAXon, Drug: Tacrolimus

**Conditions:**

Bone, Joint & Muscle

**Keywords:**

Clinics and Surgery Center (CSC), DMD, Duchenne Muscular Dystrophy, Muscular Dystrophy

### More Information

**Description:** This study aims to find out whether MyoPAXon, a genetically modified cellular therapy treatment, is safe to give to patients with Duchenne Muscular Dystrophy (DMD), and whether it has any positive effect on their disease. It will also determine how much MyoPAXon is safe to give to a person at one time.

**Study Contact:** Peter Kang - [pkang@umn.edu](mailto:pkang@umn.edu)

**Principal Investigator:** Peter Kang

**Phase:** PHASE1

**IRB**

**Number:** STUDY00023008

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.